MA38724B1 - Formulation liquide stable d'amg 416 (velcalcétide) - Google Patents

Formulation liquide stable d'amg 416 (velcalcétide)

Info

Publication number
MA38724B1
MA38724B1 MA38724A MA38724A MA38724B1 MA 38724 B1 MA38724 B1 MA 38724B1 MA 38724 A MA38724 A MA 38724A MA 38724 A MA38724 A MA 38724A MA 38724 B1 MA38724 B1 MA 38724B1
Authority
MA
Morocco
Prior art keywords
velcalctide
amg
liquid formulation
stable liquid
formulation
Prior art date
Application number
MA38724A
Other languages
English (en)
Other versions
MA38724A1 (fr
Inventor
Derek Maclean
Qun Yin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38724(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA38724A1 publication Critical patent/MA38724A1/fr
Publication of MA38724B1 publication Critical patent/MA38724B1/fr

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation liquide comprenant un agoniste peptidique du récepteur sensible au calcium, et un procédé de préparation et d'utilisation de cette formulation.
MA38724A 2013-06-28 2014-06-27 Formulation liquide stable d'amg 416 (velcalcétide) MA38724B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (fr) 2013-06-28 2014-06-27 Formulation liquide stable d'amg 416 (velcalcétide)

Publications (2)

Publication Number Publication Date
MA38724A1 MA38724A1 (fr) 2017-03-31
MA38724B1 true MA38724B1 (fr) 2017-11-30

Family

ID=51213030

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38724A MA38724B1 (fr) 2013-06-28 2014-06-27 Formulation liquide stable d'amg 416 (velcalcétide)

Country Status (38)

Country Link
US (4) US9820938B2 (fr)
EP (3) EP3878433A1 (fr)
JP (1) JP6027708B2 (fr)
KR (1) KR102231957B1 (fr)
CN (2) CN114376970A (fr)
AP (1) AP2015008936A0 (fr)
AR (1) AR096773A1 (fr)
AU (1) AU2014302122B2 (fr)
CA (1) CA2916222C (fr)
CL (1) CL2015003738A1 (fr)
CR (2) CR20160002A (fr)
CY (1) CY1120811T1 (fr)
DK (1) DK3013318T3 (fr)
EA (1) EA030220B1 (fr)
ES (1) ES2633989T3 (fr)
HR (1) HRP20171092T1 (fr)
HU (1) HUE034209T2 (fr)
IL (1) IL243210B (fr)
JO (1) JO3817B1 (fr)
LT (1) LT3013318T (fr)
MA (1) MA38724B1 (fr)
ME (1) ME02818B (fr)
MX (1) MX2015017952A (fr)
MY (1) MY180276A (fr)
PE (2) PE20160549A1 (fr)
PH (1) PH12015502816B1 (fr)
PL (1) PL3013318T3 (fr)
PT (1) PT3013318T (fr)
RS (1) RS56238B1 (fr)
SG (1) SG11201510647TA (fr)
SI (1) SI3013318T1 (fr)
SM (1) SMT201700401T1 (fr)
TN (1) TN2015000569A1 (fr)
TW (1) TWI635874B (fr)
UA (1) UA115373C2 (fr)
UY (1) UY35636A (fr)
WO (1) WO2014210489A1 (fr)
ZA (1) ZA201600238B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38724B1 (fr) 2013-06-28 2017-11-30 Amgen Inc Formulation liquide stable d'amg 416 (velcalcétide)
RS60187B1 (sr) 2014-04-03 2020-06-30 Amgen Inc Metoda za pripremanje amg 416
ES2806200T3 (es) * 2015-03-26 2021-02-16 Amgen Inc Método en fase de disolución para preparar etelcalcetida
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
CA3178367A1 (fr) 2020-05-15 2021-11-18 Rainer Oberbauer Methodes de traitement de l'hypertrophie ventriculaire gauche
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (fr) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Formulations d'ételcalcetide à usage parentéral
EP4333805A1 (fr) 2021-05-06 2024-03-13 Amgen Inc. Formulations d'ételcalcétide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938557B1 (fr) 1996-10-25 2000-09-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Procede et compositions pour inhiber des inflammations et des angiogeneses comprenant une sous-unite de cd97 alpha de mammiferes
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
EP1633390B1 (fr) 2003-06-03 2012-01-18 Novo Nordisk A/S Compositions pharmaceutiques de peptides glp-1 stabilisees
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2989778C (fr) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Methode de modification de compositions peptides
EP2264138B2 (fr) 2009-06-19 2023-03-08 The Procter & Gamble Company Composition de détergent liquide pour lavage de la vaisselle à la main
US8999932B2 (en) * 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
EP2399604A1 (fr) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
WO2012075375A1 (fr) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Administration d'hormones parathyroïdiennes par des systèmes de micro-injection
HRP20161566T1 (hr) 2011-06-08 2017-02-24 Kai Pharmaceuticals, Inc. Terapijski agensi za reguliranje serumskog fosfora
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法
MA38724B1 (fr) 2013-06-28 2017-11-30 Amgen Inc Formulation liquide stable d'amg 416 (velcalcétide)
RS60187B1 (sr) * 2014-04-03 2020-06-30 Amgen Inc Metoda za pripremanje amg 416

Also Published As

Publication number Publication date
JP6027708B2 (ja) 2016-11-16
EA030220B1 (ru) 2018-07-31
SG11201510647TA (en) 2016-01-28
PH12015502816A1 (en) 2016-03-21
BR112015032615A2 (pt) 2017-07-25
ES2633989T3 (es) 2017-09-26
JP2016523916A (ja) 2016-08-12
IL243210A0 (en) 2016-02-29
PL3013318T3 (pl) 2018-03-30
PE20210413A1 (es) 2021-03-04
AU2014302122B2 (en) 2018-12-06
SI3013318T1 (sl) 2017-11-30
CA2916222A1 (fr) 2014-12-31
EP3878433A1 (fr) 2021-09-15
LT3013318T (lt) 2017-09-11
MX2015017952A (es) 2016-10-28
PH12015502816B1 (en) 2016-03-21
US20180080452A1 (en) 2018-03-22
CY1120811T1 (el) 2019-12-11
CN114376970A (zh) 2022-04-22
CA2916222C (fr) 2021-05-18
MY180276A (en) 2020-11-26
AR096773A1 (es) 2016-02-03
HK1222557A1 (en) 2017-07-07
MA38724A1 (fr) 2017-03-31
NZ715403A (en) 2020-10-30
JO3817B1 (ar) 2021-01-31
US9820938B2 (en) 2017-11-21
CR20160002A (es) 2018-02-13
US10344765B2 (en) 2019-07-09
KR20160043954A (ko) 2016-04-22
ZA201600238B (en) 2017-05-31
US20160220486A1 (en) 2016-08-04
WO2014210489A1 (fr) 2014-12-31
HRP20171092T1 (hr) 2017-10-06
CL2015003738A1 (es) 2016-12-09
US20190285074A1 (en) 2019-09-19
TW201542239A (zh) 2015-11-16
UA115373C2 (uk) 2017-10-25
EP3246017B1 (fr) 2021-03-24
US20220042515A1 (en) 2022-02-10
CN105764487A (zh) 2016-07-13
SMT201700401T1 (it) 2017-09-07
TN2015000569A1 (en) 2017-04-06
KR102231957B1 (ko) 2021-03-25
AU2014302122A1 (en) 2016-01-21
EP3013318B1 (fr) 2017-04-19
US11162500B2 (en) 2021-11-02
DK3013318T3 (en) 2017-08-07
IL243210B (en) 2020-02-27
PE20160549A1 (es) 2016-06-15
US11959486B2 (en) 2024-04-16
ME02818B (fr) 2018-01-20
TWI635874B (zh) 2018-09-21
EP3013318A1 (fr) 2016-05-04
UY35636A (es) 2015-01-30
PT3013318T (pt) 2017-07-24
EP3246017A1 (fr) 2017-11-22
RS56238B1 (sr) 2017-11-30
AP2015008936A0 (en) 2015-12-31
EA201690099A1 (ru) 2016-06-30
CR20160061A (es) 2016-09-28
HUE034209T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
MA38724B1 (fr) Formulation liquide stable d'amg 416 (velcalcétide)
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
CL2012001853A1 (es) Formulación farmacéutica que comprende un anticuerpo humano que se une de modo especifico al receptor de interleuquina 6 humana (hil-6r), histidina y un carbohidrato.
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
EP2903971A4 (fr) Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
EP2903972A4 (fr) Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
MX2018013234A (es) Sintesis de indazoles.
MX387228B (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos.
AR095639A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario con el uso de un dispositivo móvil del usuario
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
SA516370737B1 (ar) Cgrp صيغ لمضادات مستقبل
BR112018072020A2 (pt) semaglutida em condições cardiovasculares
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
CL2014001871A1 (es) Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende.
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
MX385940B (es) Nuevos antiestrógenos heterocíclicos.
AR098556A1 (es) Aparato para procesar información, aparato de difusión y método de recepción
PH12016500044B1 (en) Vasopressin-2 receptor agonists
MX2017000519A (es) Derivados de azaspiro(4.5)decano sustituido.